Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells

Authors:
  • LLLjuba Lyass
    Ljuba Lyass
  • PTPatricia B. Trusk
    Patricia B. Trusk
  • KPKaren J. Pry
    Karen J. Pry
  • RWRobert L. Wappel
    Robert L. Wappel
  • SBSarah S. Bacus
    Sarah S. Bacus
Publisher website
Google Scholar
Abstract
ErbB2 targeted therapies represent an attractive strategy in breast cancer. Herceptin, an anti-ErbB2 monoclonal antibody, is an approved treatment for patients with ErbB2-overexpressing breast canc...